ATE460423T1 - Verfahren und zubereitungen zur zerstörung bestimmter proteine - Google Patents
Verfahren und zubereitungen zur zerstörung bestimmter proteineInfo
- Publication number
- ATE460423T1 ATE460423T1 AT98923415T AT98923415T ATE460423T1 AT E460423 T1 ATE460423 T1 AT E460423T1 AT 98923415 T AT98923415 T AT 98923415T AT 98923415 T AT98923415 T AT 98923415T AT E460423 T1 ATE460423 T1 AT E460423T1
- Authority
- AT
- Austria
- Prior art keywords
- ansamycin
- compounds
- targeting
- alone
- moiety
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4645197P | 1997-05-14 | 1997-05-14 | |
| PCT/US1998/009805 WO1998051702A1 (en) | 1997-05-14 | 1998-05-14 | Methods and compositions for destruction of selected proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE460423T1 true ATE460423T1 (de) | 2010-03-15 |
Family
ID=21943529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98923415T ATE460423T1 (de) | 1997-05-14 | 1998-05-14 | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6670348B1 (de) |
| EP (1) | EP1023315B1 (de) |
| JP (2) | JP4903922B2 (de) |
| AT (1) | ATE460423T1 (de) |
| CA (1) | CA2287387C (de) |
| DE (1) | DE69841549D1 (de) |
| WO (1) | WO1998051702A1 (de) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE473759T1 (de) * | 1998-05-22 | 2010-07-15 | Univ Leland Stanford Junior | Bifunktionelle moleküle sowie darauf basierende therapien. |
| WO2000045805A2 (en) * | 1999-02-08 | 2000-08-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of inhibiting the hgf-met-upa-plasmin network with geldanamycin derivates |
| AU769235B2 (en) * | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| EP1229924A4 (de) | 1999-11-19 | 2004-12-15 | Univ Leland Stanford Junior | Gezielte bifunctionelle moleküle und darauf gegründete therapien |
| US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| US6887842B1 (en) | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
| ATE526019T1 (de) * | 2000-07-28 | 2011-10-15 | Sloan Kettering Inst Cancer | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen |
| AU2002228771B2 (en) | 2000-11-02 | 2007-10-25 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to HSP90 |
| JP2004529188A (ja) | 2001-05-23 | 2004-09-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 上昇に関連した癌の治療法 |
| GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| US6872715B2 (en) | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| EP1440072A4 (de) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | Purinanaloga mit hsp90-inhibierender wirkung |
| EP1472230B1 (de) | 2002-02-08 | 2009-06-17 | Conforma Therapeutic Corporation | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
| US7230139B2 (en) | 2002-12-05 | 2007-06-12 | Gemin X Biotechnologies | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| ES2432747T3 (es) | 2003-06-27 | 2013-12-05 | Kyowa Hakko Kirin Co., Ltd. | Inhibidores de proteínas de la familia HSP90 |
| NZ546611A (en) | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| US7259156B2 (en) * | 2004-05-20 | 2007-08-21 | Kosan Biosciences Incorporated | Geldanamycin compounds and method of use |
| US20080171687A1 (en) * | 2004-09-16 | 2008-07-17 | Abraxis Bioscience, Inc. | Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs |
| EP1799652A1 (de) * | 2004-10-13 | 2007-06-27 | Wyeth | N-benzolsulfonyl-substituierte anilino-pyrimidin-analoga |
| CN101039952A (zh) * | 2004-10-13 | 2007-09-19 | 惠氏公司 | 作为pi3k抑制剂的17－羟基渥曼青霉素类似物 |
| BRPI0609509A2 (pt) | 2005-03-30 | 2010-04-13 | Conforma Therapeutics Corp | composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável |
| EP1940386A4 (de) * | 2005-09-01 | 2010-06-23 | Beth Israel Hospital | Wortmannin-konjugate und verwendungen davon |
| WO2007131034A1 (en) * | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| WO2008099414A1 (en) * | 2007-02-13 | 2008-08-21 | Council Of Scientific & Industrial Research | NOVEL CATIONIC 17 α- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT |
| TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
| EP2132212A1 (de) * | 2007-04-05 | 2009-12-16 | Wyeth a Corporation of the State of Delaware | Wortmannin-rapamycin-konjugat und anwendungen davon |
| WO2011044394A1 (en) | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| EP2588129A4 (de) * | 2010-06-30 | 2014-07-09 | Univ Brandeis | Auf kleine moleküle zielender proteinabbau |
| EP2694505B1 (de) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90-inhibitoren |
| EP2694506B1 (de) | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Hsp90-inhibitoren |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| US20150119435A1 (en) * | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| CN108137507A (zh) | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
| EP3337476A4 (de) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Verbindungen und verfahren für den gezielten abbau von bromdomänenhaltigen proteinen |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| ES2975558T3 (es) | 2016-09-15 | 2024-07-09 | Arvinas Inc | Derivados de indol como degradantes de receptor de estrógeno |
| LT3660004T (lt) | 2016-10-11 | 2023-06-12 | Arvinas Operations, Inc. | Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai |
| EP3535265A4 (de) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | Auf tau-protein abzielende protacs und zugehörige verfahren zur verwendung |
| WO2018102725A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| EP3559006A4 (de) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | Verbindungen und verfahren zum gezielten abbau von fetalen leberkinasepolypeptiden |
| EP3558994A4 (de) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | Verbindungen und verfahren zum gezielten abbau von schnell beschleunigten fibrosarkom-polypeptiden |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| EP3577109A4 (de) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | Cereblonliganden und bifunktionale verbindungen damit |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| WO2020206608A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| ES3061133T3 (en) | 2019-08-26 | 2026-03-31 | Arvinas Operations Inc | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| US12310975B2 (en) | 2019-10-17 | 2025-05-27 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| EP4077309A1 (de) | 2019-12-19 | 2022-10-26 | Arvinas Operations, Inc. | Verbindungen und verfahren für gezielten abbau des androgenrezeptors |
| EP4146642A1 (de) | 2020-05-09 | 2023-03-15 | Arvinas Operations, Inc. | Verfahren zur herstellung einer bifunktionellen verbindung, ultrareine formen der bifunktionellen verbindung und dosierungsformen damit |
| EP4204418A1 (de) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Schnell beschleunigende fibrosarkomproteinabbauende verbindungen und zugehörige verfahren zur verwendung |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| CA3214806A1 (en) | 2021-04-16 | 2022-10-20 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| EP4584258A1 (de) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Schnell beschleunigte fibrosarkom (raf)-abbauende verbindungen und zugehörige verfahren zur verwendung |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| DE3907290A1 (de) * | 1989-03-07 | 1990-09-13 | Gerhard Prof Dr Eisenbrand | Steroidhormonrezeptoraffine antitumorwirkstoffe |
| US5650430A (en) | 1990-06-06 | 1997-07-22 | Sankyo Company, Limited | Radicicol derivatives, their preparation and their anti-tumor activity |
| WO1994029327A1 (en) * | 1993-06-07 | 1994-12-22 | British Technology Group Limited | Anticancer compounds |
| US5932566A (en) | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5911995A (en) * | 1994-08-19 | 1999-06-15 | Regents Of The University Of Minnesota | EGF-genistein conjugates for the treatment of cancer |
| JPH11507535A (ja) * | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| ATE266017T1 (de) | 1996-10-25 | 2004-05-15 | Kyowa Hakko Kogyo Kk | Radicicolderivate |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
-
1998
- 1998-05-14 WO PCT/US1998/009805 patent/WO1998051702A1/en not_active Ceased
- 1998-05-14 CA CA2287387A patent/CA2287387C/en not_active Expired - Fee Related
- 1998-05-14 DE DE69841549T patent/DE69841549D1/de not_active Expired - Lifetime
- 1998-05-14 EP EP98923415A patent/EP1023315B1/de not_active Expired - Lifetime
- 1998-05-14 AT AT98923415T patent/ATE460423T1/de not_active IP Right Cessation
- 1998-05-14 JP JP54951698A patent/JP4903922B2/ja not_active Expired - Fee Related
- 1998-05-14 US US09/403,434 patent/US6670348B1/en not_active Expired - Fee Related
-
2009
- 2009-08-11 JP JP2009186660A patent/JP2009256388A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2287387C (en) | 2010-02-16 |
| EP1023315A1 (de) | 2000-08-02 |
| DE69841549D1 (de) | 2010-04-22 |
| CA2287387A1 (en) | 1998-11-19 |
| EP1023315B1 (de) | 2010-03-10 |
| EP1023315A4 (de) | 2004-12-29 |
| JP2001525824A (ja) | 2001-12-11 |
| JP4903922B2 (ja) | 2012-03-28 |
| JP2009256388A (ja) | 2009-11-05 |
| US6670348B1 (en) | 2003-12-30 |
| WO1998051702A1 (en) | 1998-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69841549D1 (de) | Verfahren und zubereitungen zur zerstörung bestimmter proteine | |
| Mahmoodzadeh Hosseini et al. | Staphylococcal entorotoxin B anchored exosome induces apoptosis in negative esterogen receptor breast cancer cells | |
| WO2003030934A3 (en) | Cpg formulations and related methods | |
| BR0312421A (pt) | Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos | |
| BR0313733A (pt) | Uso da proteìna n beta cinase | |
| DE69737867D1 (de) | Zielgerichtete kombinations-immuntherapie für krebs | |
| BR0312456A (pt) | Anticorpo alterado ou fragmento funcional do mesmo, polinucleotìdeo, sequência de polinucleotìdeo, composição farmacêutica, métodos de tratamento ou profilaxia de derrame e outras doenças/distúrbios neurológicos em um ser humano, de inibição da neurodegeneração e/ou promoção da recuperação funcional e de promoção do desenvolvimento axonial, e, uso de um anticorpo anti-mag | |
| DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| PT983087E (pt) | Composicao de vacina multivalente com veiculo misto | |
| EP1423107A4 (de) | Fettalkohol-arzneimittel-konjugate | |
| AR024074A1 (es) | FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS. | |
| ES2110097T3 (es) | Sistema de liberacion basado en proteinas. | |
| BR9711805A (pt) | Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos | |
| BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
| BR0111355A (pt) | Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos | |
| DE60006280D1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
| ES2206689T3 (es) | Agentes de contraste. | |
| UA49796C2 (uk) | Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція | |
| DE69531342D1 (de) | Avidin-biotin immunokonjugate | |
| DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
| BR9811094A (pt) | Agente terapêutico para tumores linfáticos | |
| BR0207487A (pt) | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona | |
| AU3142597A (en) | Dha-pharmaceutical agent conjugates | |
| BR0111892A (pt) | Bis-arilsulfonas | |
| AU2003277280A8 (en) | Biphenyls and fluorenes as imaging agents in alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |